3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis

Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA), and associated with improved Health-Related Quality of Life (HRQoL) in a substantial proportion of children with JIA.

Read the whole article on Physorg

More from Physorg